The Three Beauties of Biomedical Research. Gaze on them admiringly:
It is the best of times when an informed populace demands health information, preventive services, and healthier products and environments and leadership is responsive to the demand; when death rates fall dramatically, indicating the dynamic nature of CVD processes and providing impetus to prevention research, policy, and interventions; when medical and social forces join enthusiastically in the control and prevention of elevated blood pressure and blood cholesterol levels, it is socially unacceptable for physicians to smoke, and the cultural climate evolves rapidly toward supporting healthy behaviors.
It is the best of times when the National Institutes of Health (NIH), the American Heart Association (AHA), and other health agencies establish clear policy, set goals, monitor progress, and support a broad strategy of preventive research and programs in CVD prevention. 3 The Worst of Times But it is also the worst of times when there is a major opportunity and need for research and programs in CVD prevention among many segments of society and when these are nowhere near a high government priority; when biomedical research and development, one remaining area of acknowledged national excellence and source of jobs and economic stimulus, is not among the highest government priorities; when the accelerated costs of doing research and administering programs are entrapped in a linear NIH budget, and the proportional annual increments for the National Heart, Lung, and Blood Institute (NHLBI), the leader of NIH in planning and strategy for prevention, are substantially diminished.
It is the worst of times when the long touted and essential balance of NIH research and program strategies is threatened by competition for resources and by a certain elitism about what is exciting and important in science, and "the baroque beauty of biology" threatens its counterpart, the "classic beauty of epidemiology."
Contributions of Epidemiology As a background to understanding, let us recount what epidemiology contributes, as a major research method and as the basic science of prevention, to the scientific community, to preventive practice, and to the public health.
First, epidemiology is both a basic and applied science; it rigorously explores questions without an immediate application as well as addressing pragmatic issues in practice and public health.
Epidemiology contributes the evidence about population differences in disease rates and risk and documents their dynamic changes. This provides the prime evidence that mass cultural phenomena are the main determinants of population risk. This is the central fact that leads to the strong possibility of CVD prevention in whole populations.
Epidemiological monitoring offers the basic descriptors of CVD in the population-of secular Finally, epidemiology provides the sound basis for an effective and responsible public health policy, a policy based on the best available evidence at any given time.
Often, it is the epidemiologist who is called on to synthesize the evidence derived from all the major research strategies, to point out its public health implications, and to formulate policy recommendations.
For all these reasons, it is increasingly important that the medical community, having as its primary mission the care of patients, and academia, concerned mainly with mechanisms, understand better the major contributions of epidemiology in the context of the rapidly changing picture of CVD. It is essential that academic leaders understand epidemiology as a necessary and complementary discipline and that they support the goals of prevention research and policy irrespective of their personal interest or participation in such undertakings. Often the sole "epidemiological type" among 20 or so members of the NHLBI Advisory Council, I find that this much understanding is essential to the proper exercise of judgment and power, the power that clinical and bench investigators derive from their numbers and status in the advisory function and direction of our research institutions. The natural tension between the views and motivations of bench and clinical investigators on the one hand and population investigators on the other is tolerable when it occurs within a framework of mutual understanding -that the three main research methods are complementary and equally necessaryand where competent peer review exists for each disci- These different views also translate into a different tolerance for uncertainty and sometimes even to a different ability to take rational health actions in the nothing school" of preventive practice bases its views on the fact that we "don't know enough" (in fact, we rarely ever know "enough"). This exclusively individual focus translates further into an opinion that epidemiology is only "statistics," not "mechanisms," and therefore, is not "science." It is expressed by the attitude that current measures of CVD risk and ways of lowering risk are "crude and simplistic." At best, this attitude translates into the position I have heard expressed that population preventive strategies may be "all right for now, but, just around the corner, when we are able to know the locus of each defect in each individual, then we can return to a more rational, sophisticated strategy, one that discriminates individual risk and avoids bludgeoning the whole population with lifestyle changes!" In fact, science moves forward by progressively exposing, then adding new layers; knowledge is never finite or complete.
I submit that it does not deprecate the important and exciting role of genetics and microbiology in bringing improved risk detection in the individual to suggest that this precision cannot obviate the wide-ranging effects of multiple genes and exposures, acting together through multiple body systems, to regulate the multiple physiological risk characteristics involved in the pathogenesis of CVD. Clearly, knowledge of the population distribution of genes and their epidemiological associations will enhance understanding of the genetic contribution to mass diseases. But this new and fundamental knowledge cannot account for the many health behaviors, due to multiple cultural influences, that interact with multiple genes to produce elevated disease risk -both in individuals and in populations. The "precious" view that science will eventually know and control the locus for every defect cannot, in fact, embrace whole generations of youth or set them on a healthy behavioral pathway-to a healthy metabolic pathway-to a low risk of disease as adults. The specific, individual approach to CVD cause and prevention cannot create the professional and societal attitudes needed to change the mass determinants of CVD risk. I suggest that the current intellectual excitement about genetic precision is in no way reduced by the fact that such precision cannot account for the predominantly social determinants of the frequency of major risk phenotypes or for the large population burden of the common chronic diseases. Finally, high-tech, high-cost, cardiological strategies, individually accurate and lifesaving as they have now become, cannot enhance personal lifestyles-or create a healthy society-or prevent high risk in the first place! Value Systems There are other major influences of the different value systems that surround the population and the individual approaches to disease. One system, from a view of the whole over time, believes that humanity can better itself through changes in behavior and changes in its institutions. The other, from a strong sense of the complexity of life and its substantial individual predestination by genes, resists any preventive action that affects private behavior, even when it is democratically achieved.
These different values can result in conceptual incon- Congress has mandated that a given, high number of grant awards be issued annually by NIH, which, in effect, reduces the amount of money available per grant award. Congress has mandated also that NIH cannot in the future reduce the grant amounts recommended by peer review. Formerly, "downward negotiation" was a customary way of redistributing funds.
The research pot, boiling high now in a competitive stew, has a new influx of ingredients; the numbers of grant applications have soared, as have the costs of review, and of re-review.
A $1 million federal cap has been placed on all program projects and a 4% cap on grant budget augmentations after the first year with a 10% cap on renewal budget increases. But fully operational, lateryear budgets for epidemiological studies and clinical trials are characteristically and necessarily 50-100% greater than their earlier year budgets that cover only protocol development, observational and pilot activity. These caps and rules apply only to new awards, but existing large awards have been cut as much as 25% on continuation, severely jeopardizing their scientific integrity and feasibility. A whole class of research activity is selectively and severely crippled by such arbitrary blanket regulations.
Furthermore, proposed federal caps on indirect cost allocations to research institutions will, at the very least, eliminate the sole source of developmental funds and new research enterprise in many departments of universities. It will have an equally serious effect on research facilities.
Federal fiscal "games," to defer current NIH awards to reduce the apparent national deficit, will have serious consequences including delayed funding, 10-month instead of 12-month funding, a 2-month period without local authority, and a potential nightmare of excess funds for NIH to manage come the end of the fiscal year. The NHLBI Value Function is computed from total costs of a grant raised to the 1/4th power, multiplied by the percentile priority from peer review.
NIH Administrative Reactions
Administrative reactions by NHLBI to these and other fiscal strains have generally been thoughtful, well-intended efforts to keep the research establishment afloat, to maintain a balanced research program, and to reconcile the monies available with the number of grants mandated. But all of these administrative reactions affect the whole scientific community profoundly. I voice the particular concern here that these changes selectively affect epidemiological and prevention researches that, because of their nature, organization, and costs, are especially vulnerable. Larger and long-term grants, characteristic of epidemiological studies in sizable human populations, present a particular problem for NHLBI. Overall, less than 6% of awards consume one third of its grant resources. In consequence, NHLBI now computes and applies a "value function" that enters the total cost of a grant proposal, as well as its scientific merit, into the funding decisions for the main lines of research grants and program projects. This is another well-intentioned effort to match the mandated number of grants with the funds available in those budget lines, but it will have major consequences for larger grants. Because grant awards can no longer be reduced in dollar amount by NIH staff or councils, again due to Congressional mandate, the value function is employed, taking into consideration the first year total cost of a proposal with its priority percentile rank:
Value function=(priority percentile) x (total cost)`14
In Table 1 , if the cutoff for funding occurred at a value function of 88, for example, all $150,000 grants would be funded up to the 25th percentile and all $400,000 grants excluded above the 20th percentile. A $1 million grant would require a 20th percentile rank to compete with a $250,000 grant at the 30th percentile of merit, and so on.
The upshot of this model is that for value functions falling around the funding cutoff, peer review is bypassed and smaller grants are awarded in preference to larger ones at the same or superior scientific merit.
In other developments, NHLBI Program Project applications just failing the payline are now being "disaggregated" into their fundable meritorious components, to the competitive disadvantage of RO1 grants and other program projects. Moreover, all new grants of $400,000 or more now require "prior consultation" with NHLBI staff in their preparation. The "constitutionality"' of this requirement has not been tested, but most investigators comply with and generally profit from discussions with NHLBI staff. If, however, an investigator-initiated effort does not succeed in peer review, yet is considered sufficiently important by staff and council, NHLBI may then take the research initiative. This, in effect, puts the NIH in competition with the community of investigators. Even though such institute initiatives fall within a separate NHLBI budget allocation, in the end, "everything competes with everything else" for the limited funds. The investigators who made the original proposal are, in effect, blocked from pursuing investigator-initiated enterprise of a similar nature.
Another new, across-the-board regulation by NHLBI requires that all epidemiological-type proposals specifically costing $500,000 or more be placed under "cooperative agreements" rather than being awarded as grants. This rule was born out of an NIH-perceived need for large-grant accountability and presumably some occasions of inadequate performance of clinical trials, for example. The rule, in fact, increases NIH control and direction of research and selectively affects the freedom of investigators involved in epidemiological and prevention pursuits. Though there are valid reasons for cooperative agreements, and many of them function very well, the need for such a blanket rule should be thoroughly documented by NHLBI and discussed beforehand with that part of the scientific community most affected. The regulation was passed by the NHLBI Advisory Council and not recognized as yet another incursion into the independence of all CVD investigators.
All in the CVD research community would likely agree that it is essential and past due that epidemiological researches address a number of relatively neglected areas in women's and minority health. All would likely agree that a research agenda dominated by white male subjects is inappropriate and incomplete. But a blanket rule now affects the feasibility and cost of all epidemiological studies, quite independent of the scientific questions addressed. All epidemiological studies and clinical trials of $500,000 or more, unless clearly justified, are required, in effect, to have sufficient numbers of minorities and women in which to test subgroup hypotheses, with profound consequences on the cost, feasibility, and competitiveness of grants in the field. NIH research into these critical health issues should be vigorously pursued and rigorously planned with the goal to achieve the best answers, through the most appropriate populations, within the strongest study designs. But this simply cannot occur under such a blanket regulation for all epidemiological studies, which amounts to "politically correct" science.
"Programmatic review" by the NHLBI Advisory Council is now mandatory on all grants of $500,000 or more. This added level of review, again, tends to select against large proposals, therefore, against many epidemiological study proposals.
There is reason for concern, in addition, about administrative tampering with the excellent NIH peerreview process. Parent review committees, individual institute review groups, and site visits to applicants' institutions are being abolished. These and other major changes are underway or under consideration by the Division of Research Grants and by an NIH Task Force on Peer Review. It has taken years to develop experienced and skilled review in many fields of research, particularly in epidemiology, prevention, and behavioral researches. The ongoing changes threaten this competence. Needs for change in the NIH peer-review process should be most carefully documented and widely and consultatively considered and actual changes initiated very cautiously.
Discussion
All these trends involving the U.S. economy and the NIH budget, congressional mandates, and public stewardship of resources, along with the administrative responses of NIH, originate from different value systems, enthusiasms, and pressures. They create a major challenge for those of the "epidemiological persuasion" as well as for the larger scientific community. In observing these trends, some have suspected a mindset, even a "conspiracy" against epidemiology, large grants, and program projects. But a conspiracy takes a great deal of planning! In fact, it is rare that NIH Council reviewers exchange views at all on individual grants or on substantive policy issues. Even in the small NHLBI Committee on Working Program, which I like to characterize as the "Gang of Four," opinions are expressed openly, no agenda are set, and no one goes to Council with a strategy for who will talk first or who will support what. On the other hand, informal views of members of Council are widely heard in NIH corridors at meeting time: "I couldn't care less about these epidemiological studies!" "Is that community trial going to go on forever?" "Don't those guys know that it is 1991!" "This isn't science! Well, if it's science, it isn't research!" "Epidemiology had its heyday in the 1960s and 1970s; other things are more interesting now." No, there is no conspiracy; perhaps there is only ignorance of the broad spectrum of research needed, and bias against certain colors of that spectrum! What is new in this painful and highly competitive picture today derives mainly, of course, from the economic "crunch," but it is accentuated by congressional hands-on policies and by vigorous and hasty "topdown" responses of NIH management to the federal mandates and fiscal crisis. In consequence, the entire community of biomedical investigators is now anxious and upset. What seems to be missing is an over-arching public and congressional understanding of, and mandate for expanded biomedical research in all lines, including epidemiology and prevention. What is missing also is an ongoing forum for bringing the concerned parties together to analyze and respond, to resolve issues, and to plan. Dr. Healy has attempted a worthwhile, one-of-a-kind consultative approach to the current NIH strategic plan.
Where to? Where, then, do we go from here in respect to the special interests of epidemiology and prevention science but also in our larger obligation to biomedical First, as investigators, we would do well to document better our problems and articulate better our ideas and arguments, attempting ways of resolving important issues that are preferable to simply accepting NIH "solutions" passively, or "bellyaching" loudly about them, or, more seriously, bypassing the system to activate the "loose cannons" on the decks of Congress and in the media! Our next priority should be to focus on doing a good job with what we now have in the NHLBI research "portfolio." The major CVD cohort studies underway must be carefully nurtured, impeccably managed, and their data fully exploited so that they may become the "new Framinghams." They present a remarkable opportunity to study new risk characteristics among cohorts of youth, adults and the elderly, women, and minorities to acquire new knowledge about etiology and about the force of risk factors in a rapidly changing U.S. culture. Indeed, there is every evidence that the current generation of studies is improved in design and is highly productive. These valuable epidemiological undertakings can best be preserved by continued good work.
We need to learn from costly happenings of the past that have contributed much to the negative attitudes of bench and clinical colleagues about trials and other epidemiological undertakings. As investigators, we clearly made mistakes and perhaps we failed to protest sufficiently some mistakes thrust upon us, in the designs, end points, and sample size estimates, for example, of the Multiple Risk Factor Intervention Trial and the Lipid Research Centers Program and conceivably of the large public health trials and community studies of the last decade. On the other hand, we have not summarized effectively the positive accomplishments, and presumably, the money well spent, of such recent successes as the CAST, SHEP, SOLVD, and TOPH trials, nor pointed out how CAST, for example, has led to a complete rethinking of generations of medical therapy directed at suppressing ectopic beats to prevent more serious arrhythmias.
For new proposals in epidemiology and prevention, we must be particularly innovative, using more objective markers of physiological and sociobehavioral characteristics studied in stronger and more efficient designs (such as case-control studies nested within populationbased cohorts). Postal studies with mortality follow-up of huge cohorts might be applied more widely to occupational and social groups, even to magazine subscription populations, giving a rapid yield on simple questions and self-administered measurements. Two Just as the growing dependence of members of Congress on special interest funds tends to corrupt government, so, too, it corrupts the scientific process. Just as lawmakers are no longer as beholden to those who elect them, but rather to political action 'committees that finance them, so scientists may no longer be as beholden to the beauty of truth, but rather to a new support system in which their beliefs are subtly influenced by their instincts for survival! It is time that Congress cleans house. So, too, it is time that medical science cleans house! Bypassing Peer Review The increasing practice, including that of a few epidemiologists and prevention investigators, of running right away to complain to the media or to Congressional representatives when NIH review fails to result in funding, is a most serious departure from a long academic tradition. It must be avoided until all "normal" procedures are exhausted; that is, diligent study of the peer criticisms, careful discussion with experienced colleagues, direct consultation with NIH staff and directors, regrouping and resubmission of proposals. Eventually, if called for, legitimate formal NIH appeal procedures are available. The merits of a case must be weighed very carefully against damage to the peer review process, and to NIH, when influence-peddling is thrust into the picture.
Some have suggested that these days of relatively reduced NIH funding may have a salubrious "shaking out" effect on the population of medical investigators. On the NHLBI Advisory Council I have heard frequently such calls for a return to a smaller investigative elite. Interestingly, these views usually come from an already small (and senior) elite! But a broad base for the pyramid of science is probably crucial for its summit to reach high. The base of the scientific enterprise must be maintained.
Balance (Is in the Eye of the Beholder) Clearly, for epidemiology and prevention science, we must attempt systematically to redress the distorted balance of power in NIH and in voluntary agencies such as the AHA. It is unhealthy that epidemiology always be in an unrepresentative role and always in a posture of reaction rather than in a condition where disciplines and interests have equal weight. Only then can special interest be transcended for the greater, common goodwhich is a truly broad and successful national research program.
What might be an appropriate representation of the major research disciplines on scientific and governing bodies? The obvious division is 1/3, 1/3, 1/3 for laboratory, clinical, and population approaches. What expertise would effectively represent the "population" approach and what, for example, should be the composition of the major working groups, standing committees, and councils of NIH and AHA? "Our one third" would consist not only of epidemiologists but also statisticians, sociologists, anthropologists, ecologists, clinical-trialists, health economists, and preventive practitioners; and not only these, but also health policy thinkers and communicators. As effectively as NIH has learned to put together its specialty study sections and ad hoc review groups, it has not yet succeeded in composing its major councils, working committees, task forces, and planning groups to include an appropriate representation of skills, experience, and vision from epidemiologists, preventive practitioners, or public health experts.
With a view to improving collaboration needed among such critical U.S. agencies as the NIH, USDA, IOM, and congressional staffs, useful models exist. For example, there was a particularly fruitful collaboration between NIH, HEW, and the USDA during the Carter Administration where for the first and perhaps only time in history, agencies for health and agriculture took each other's needs and constituencies into consideration. Not only is a mechanism needed for long-term planning but for short-term responsiveness. The scientific community and its professional organizations should lead in taking up research initiatives, bringing quickly on board the institutes and, finally, the Congress, to consider needed programs, using an ongoing process of thoughtful and timely deliberations.
Back to Basics We in epidemiology and prevention need also to return to "basic principles" of public health in applying the strong scientific evidence for health action. The population strategy seeks public education along with the promotion of healthy products, clean air and water, and on occasion it seeks regulations, passive restraints and controlled access. "Luxury" taxes and other strategies need to be applied toward industries that, in effect, manufacture excess deaths, including tobacco, chemicals and drugs, and guns. We should seek democratically, but vigorously and innovatively, to change institutions and industries and their unhealthy products, with positive efforts to promote healthy community behaviors.
Communications
We need to call attention directly, in our scientific and public communications, to the messages in our results that are relevant to other disciplines, and we need to encourage others, in turn, to point out leads and approaches for our researches. If we train ourselves and future generations of investigators to look for such clues and opportunities in each others findings, greater understanding and mutual respect would surely result.
It is also time for us to speak up, to organize, and to deal squarely with the NIH, with voluntary agencies, and with the Congress. We must be forthright, vigorous and concerted, formulating our arguments clearly so that they cannot be construed as mainly self-serving (or even disloyal to the NIH establishment that we have worked so diligently to create!). But it is time now that we speak out for much broader views of what is "real science" and "basic science," always seeking patiently to persuade other colleagues to our view: that of "sick and well populations" as well as "sick and well individuals!" Finally, it is time that we document carefully the opportunity, and paint attractively for the larger community, a portrait of the benefits to be expected from a greater national investment in epidemiology and prevention research, within a spectrum of generally expanded researches, illuminating all three "beauties." The effect of stimulation of biomedical research activity in our country can only be a healthy one, on jobs, on the balance of trade, on the national economy, and on the health of individuals and whole populations.
